Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects

ConclusionsMacitentan 10 mg did not affect the pharmacokinetics of BCRP substrates, rosuvastatin or riociguat in healthy male subjects.EudraCT numbers: 2017 –003095–31 and 2017–003502–41.

http://link.springer.com/10.1007/s40261-019-00857-7

Source: Clinical Drug Investigation - September 23, 2019 Category: Drugs & Pharmacology Source Type: research